MetaCap

Absci Corporation (ABSI)

NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

7.51-0.65 (-7.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABSI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.79
52-week range
2.24 – 12.55
Day range
7.45 – 8.14
Volume / Avg
4.74M / 4.08M
Beta
—

52-week range

$2.24$12.55

ABSI stock today

Absci (ABSI) closed at $7.51 on Nov 20, down 7.97% (-$0.65), versus the S&P 500's 3.70% decline. Shares are 40.1% below their 52-week high of $12.55, set on Oct 29, 2026 and 235.3% above the 52-week low of $2.24, in the middle of the past year's range. ABSI is up 115.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 156.3%.

Absci has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Absci

Company profile

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Mr. Sean McClain
Headquarters
Vancouver, WA
Employees
140
IPO year
2021
Website
absci.com

Financial highlights

Full financials

In fiscal 2025, Absci generated $2.8 million in revenue, down 38.2% from fiscal 2024, its first annual decline since 2024. Absci reported a net loss of $115.2 million, compared with a loss of $103.1 million a year earlier. Operating margin was -4297.0%.

Absci annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.80M$4.53M$5.72M$5.75M$4.78M
Growth-38.24%-20.71%-0.50%+20.18%+0.04%
Net income$-115.18M$-103.11M$-110.57M$-104.90M$-100.96M
EPS (diluted)$-0.84$-0.94$-1.20$-1.15$-2.08

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$15.09+100.93%

  • Strong buy 2
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.17 vs $-0.14
Surprise
-21.43%

ABSI news

All ABSI news

Absci peers

Health Care sector
ABSI peer companies
CompanyPrice% ChgMarket capCompare
OABIOmniAb Inc.4.66-7.36%$679.71Mvs ABSI
NRCNRC Health25.16+0.68%$533.93Mvs ABSI
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs ABSI
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs ABSI
BIAFbioAffinity Technologies Inc.1.65-10.81%$3.00Mvs ABSI
ISPCiSpecimen Inc.0.4563-13.58%$2.64Mvs ABSI
ICLRICON plc186.71-1.92%$13.99Bvs ABSI
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs ABSI

Indexes, lists and sector

Absci stock FAQ

What is Absci's stock price today?

ABSI last traded at $7.51 as of Nov 20, 4:00 PM EST, down 7.97% on the day. Prices are delayed at least 15 minutes.

Who is Absci's CEO?

Mr. Sean McClain is the chief executive officer of Absci Corporation, which has about 140 employees.

What is the ABSI 52-week high?

The 52-week high for ABSI is $12.55 and the 52-week low is $2.24. The stock is currently 40.1% below its high.

Compare ABSI